Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.45 |
| ▸ | GSK3B | P49841 | 5/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 3/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.38 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9508765 | 0.84 | HMGB1 (0.54) | PTPN1GSK3BAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL8582898 | 0.79 | GSK3B (0.44) | PTPN1GSK3BALDH1A1 | |
| SCHEMBL4317652 | 0.77 | GSK3B (0.38) | PTPN1GSK3BAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL27968199 | 0.77 | CA12 (0.56) | AKR1C3AKR1C2AKR1C1AKR1C4HMGB1 | |
| SCHEMBL3947199 | 0.76 | PTPN1 (0.52) | PTPN1GSK3BALDH1A1HPGDHSD17B10 | |
| SCHEMBL9708883 | 0.74 | ALDH1A1 (0.52) | PTPN1GSK3BHMGB1ALDH1A1HPGD | |
| SCHEMBL2728246 | 0.74 | CA12 (0.59) | AKR1C3AKR1C2AKR1C1AKR1C4HMGB1 | |
| SCHEMBL6543881 | 0.73 | GSK3B (0.59) | PTPN1GSK3B | |
| SCHEMBL27968197 | 0.72 | CA12 (0.56) | AKR1C3AKR1C2AKR1C1AKR1C4HMGB1 | |
| SCHEMBL27968298 | 0.72 | CA12 (0.56) | AKR1C3AKR1C2AKR1C1AKR1C4HMGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | claimed |
| EP-0013783-B1 | PROTECTION OF THE GASTRIC MUCOSAL LINING FROM DAMAGE BY ASPIRIN AND RELATED DRUGS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1984-04-04 | — | — | EP | claimed |
| US-7511070-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7084171-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| EP-1038021-A4 | COMPOUNDS AND METHODS FOR THE INHIBITION OF PROTEIN-PROTEIN INTERACTIONS | WAY JEFFREY C (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | disclosed |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-20030003513-A1 | Compounds and methods for the inhibition of protein-protein interactions | WAY JEFFREY C (US) | 2003-01-02 | — | — | US | disclosed |
| US-6465192-B2 | MODULATORS OF POLYPEPTIDE BINDING ACTIVITIES; FOR USE IN THE TREATMENT, PREVENTION OF INFECTIONS AND VIRAL DISEASE | Way, Jeffrey C. | 2002-10-15 | — | — | US | disclosed |
| US-6410587-B1 | FIBROSIS; ALZHEIMER'S DISEASE; ANTIARTHRITIC AGENTS | NEORX CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-20020031780-A1 | COMPOUNDS AND METHODS FOR THE INHIBITION OF PROTEIN-PROTEIN INTERACTIONS | WAY, JEFFREY C. | 2002-03-14 | — | — | US | disclosed |
| EP-1038021-A1 | COMPOUNDS AND METHODS FOR THE INHIBITION OF PROTEIN-PROTEIN INTERACTIONS | Way, Jeffrey C. (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6117911-A | ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. | NEORX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1999031265-A1 | COMPOUNDS AND METHODS FOR THE INHIBITION OF PROTEIN-PROTEIN INTERACTIONS | WAY JEFFREY C (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1998046588-A2 | COMPOUNDS AND THERAPIES FOR THE PREVENTION OF VASCULAR AND NON-VASCULAR PATHOLOGIES | NEORX CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5013866-A | Pharmaceutical grade 3,5-dibromosalicylic acid and metohd for synthesizing same | BAXTER INTERNATIONAL INC. (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | PTPN1 1380/4885GSK3B 121/4885AKR1C3 1710/4885 |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | PTPN1 1380/4885GSK3B 121/4885AKR1C3 1710/4885 |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | PTPN1 1380/4885GSK3B 121/4885AKR1C3 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.